What is Retatrutide?
Triple agonist (GLP-1/GIP/Glucagon) showing 24%+ weight loss in trials.
Retatrutide is the first triple-agonist peptide, hitting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed unprecedented results: participants lost up to 24% of body weight at the highest dose - more than any other obesity medication tested. The glucagon component adds metabolic rate increase (thermogenesis) on top of the appetite suppression from GLP-1/GIP. Users in trials report similar "food noise" elimination as semaglutide but with potentially better energy levels due to the glucagon component. Side effects mirror other GLP-1s (nausea, GI issues) but the glucagon action may cause more initial appetite suppression. Currently in Phase 3 trials by Eli Lilly. Expected FDA submission 2025-2026. Some people are sourcing research-grade versions, though quality and purity are uncertain outside clinical trials.
What the evidence says
The overall evidence grade for Retatrutide is B (moderate — mixed or smaller trials, reasonable mechanistic support). Strong Phase 2 data showing 24% weight loss. Phase 3 ongoing.
Specific findings with supporting evidence:
- Phase 2 showed up to 24% weight loss at highest dose. Evidence grade A.
- Triple mechanism may improve on dual-agonists. Evidence grade B.
- Glucagon component increases metabolic rate. Evidence grade B.
Best-supported outcomes:
- Significant weight loss (trial data).
- Appetite suppression.
- Metabolic rate increase.
Where marketing outpaces evidence:
- The claim that "Long-term safety profile established" is not supported by the evidence (grade C).
- Marketing often overstates: Completely safe because it is in trials.
- Marketing often overstates: No different from approved GLP-1s.
Dose and timing
Take it in the morning. Weekly injection in trials.
Who it's for, and who should skip it
Most relevant for:
- Those following clinical trial developments.
- Those interested in next-gen obesity treatments.
Not appropriate for:
- Those wanting proven, approved medications.
- Risk-averse individuals.
Safety and cautions
Caution: Not yet approved. Still in Phase 3 trials. Long-term effects unknown. Important: Research sources. Quality of non-trial sources is uncertain. Caution: Novel mechanism. Triple agonism is new; glucagon effects need more study.
Common mistakes
- Assuming Phase 2 results guarantee approval.
- Using research-grade without understanding purity risks.
Myths vs reality
A common misconception: Retatrutide is just like tirzepatide. In reality, the added glucagon receptor activation is a meaningfully different mechanism.
How it interacts with other compounds
- Retatrutide works well alongside glp1 overview — evolution of GLP-1 mechanism.
Questions people ask
Why add glucagon if it raises blood sugar? The glucagon component increases energy expenditure and fat burning. The GLP-1/GIP counterbalance the glucose effects.
When will it be approved? Phase 3 trials ongoing. Optimistically 2025-2026 for FDA decision.
Editorial note
This guide summarizes the published evidence on Retatrutide. It is educational content, not medical advice. Confirm with your clinician if you take prescription medications or manage a chronic condition.